BMS mAbs: meta-analysis of COVID-19 studies

All studies Hospitalization Serious outcomes Recovery Viral clearance RCTs Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−36%

Hospitalization (1)−36%

Viral clearance (1)4%

RCTs (1)−36%

Early (1)−36%

00.511.5+

← BMS mAbs
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

BMS mAbs COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Corada (DB RCT)−36%1.36 · 0.31–5.92hosp.4/1043/106

Early treatment−36%1.36 · 0.31–5.924/1043/10636% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7

All studies−36%1.36 · 0.31–5.924/1043/10636% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.700.511.52+

Rotate screen for more detailsIncrease width for more details

← BMS mAbs
reduces riskBMS mAbs
increases risk →

c19early.org

October 2026

BMS mAbs COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Corada (DB RCT)−36%1.36 · 0.31–5.92hosp.4/1043/106

Early treatment−36%1.36 · 0.31–5.924/1043/10636% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7

All studies−36%1.36 · 0.31–5.924/1043/10636% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.700.511.52+

Rotate screen for more detailsIncrease width for more details

← BMS mAbs
reduces riskBMS mAbs
increases risk →

c19early.org

October 2026

BMS mAbs COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Corada (DB RCT)−36%1.36 · 0.31–5.92hosp.4/1043/106

Early treatment−36%1.36 · 0.31–5.924/1043/10636% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7

All studies−36%1.36 · 0.31–5.924/1043/10636% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.700.511.52+

Rotate screen for more detailsIncrease width for more details

← BMS mAbs
reduces riskBMS mAbs
increases risk →

c19early.org

October 2026

BMS mAbs COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Corada (DB RCT)20%0.80 · 0.57–1.12recov. time105 (n)106 (n)

Early treatment20%0.80 · 0.57–1.12105 (n)106 (n)20% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.19

All studies20%0.80 · 0.57–1.12105 (n)106 (n)20% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+

Rotate screen for more detailsIncrease width for more details

← BMS mAbs
reduces riskBMS mAbs
increases risk →

c19early.org

October 2026

BMS mAbs COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Corada (DB RCT)4%0.96 · 0.87–1.06viral+104 (n)106 (n)

Early treatment4%0.96 · 0.87–1.06104 (n)106 (n)4% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.45

All studies4%0.96 · 0.87–1.06104 (n)106 (n)4% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.4500.511.52+

Rotate screen for more detailsIncrease width for more details

← BMS mAbs
reduces riskBMS mAbs
increases risk →

c19early.org

October 2026

BMS mAbs COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Corada (DB RCT)−36%1.36 · 0.31–5.92hosp.4/1043/106

Early treatment−36%1.36 · 0.31–5.924/1043/10636% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7

All studies−36%1.36 · 0.31–5.924/1043/10636% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.700.511.52+

Rotate screen for more detailsIncrease width for more details

← BMS mAbs
reduces riskBMS mAbs
increases risk →

c19early.org

October 2026

BMS mAbs COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Corada (DB RCT)−36%1.36 · 0.31–5.92hosp.4/1043/106

Early treatment−36%1.36 · 0.31–5.924/1043/10636% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7

All studies−36%1.36 · 0.31–5.924/1043/10636% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.700.511.52+

Rotate screen for more detailsIncrease width for more details

← BMS mAbs
reduces riskBMS mAbs
increases risk →

c19early.org

October 2026

BMS mAbs COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Corada (DB RCT)−36%1.36 · 0.31–5.92hosp.4/1043/106 Corada (DB RCT)17%0.83 · 0.70–0.98progression104 (n)106 (n) Corada (DB RCT)20%0.80 · 0.57–1.12recov. time105 (n)106 (n) Corada (DB RCT)4%0.96 · 0.87–1.06viral+104 (n)106 (n) Corada (DB RCT)0%1.00 · 0.89–1.11viral+104 (n)106 (n) Corada (DB RCT)3%0.97 · 0.76–1.25viral+104 (n)106 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← BMS mAbs
reduces riskBMS mAbs
increases risk →